AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab

AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the HorizonOn July 24, AstraZeneca PLC (NASDAQ:AZN) announced positive results for its global Phase 3 trial of Gefurulimab in adults with generalized myasthenia gravis who are antibody-positive.

Management noted that the trial was randomized, double-blind, and placebo-controlled. It met its primary and all secondary endpoints as patients showed significant improvement in their daily activities related to gMG at 26 weeks compared to placebo. gMG is a rare autoimmune disease that causes muscle weakness and loss of function. CEO of AstraZeneca PLC (NASDAQ:AZN) Rare Disease Marc Dunoyer noted that the results confirm gefurulimab’s potential as a fast-acting and sustained treatment option. Management expects the treatment to become first-line with a good safety profile.

AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab

A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that focuses on oncology, rare diseases, cardiovascular, respiratory, immunology, and vaccines.

While we acknowledge the potential of AZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AZN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.